Humanigen (OTCMKTS:HGEN) CEO Cameron Durrant joined Steve Darling from Proactive Investors in Los Angeles at the LD Micro show to provide details about their latest research regarding the use of Car-T therapy in the treatment of certain blood cancers. That research was just published in the digital version if Blood Magazine.
Investor deep dive
Humanigen pins hopes on monoclonal antibody treatment of cancer therapy's side effects
Humanigen new research shows encouraging results for cancer treatment using Car-T
Quick facts: Humanigen Inc
Market Cap: $92.48 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen Inc named herein, including the promotion by the Company of Humanigen Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE